Aurinia Pharmaceuticals Plans to Take a Big Step Forward

After positive mid stage trial data suggested earlier this year that it might be able to reshape the treatment of kidney failure in lupus patients Aurinia Pharmaceuticals NASDAQ AUPH 160 has announced plans for a late stage study that could eventually allow it to win regulatory